ASCO Launches Online Educational Initiative: ‘Grand Rounds’

Publication
Article
OncologyONCOLOGY Vol 14 No 7
Volume 14
Issue 7

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource-ASCO Grand Rounds- for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource—ASCO Grand Rounds— for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will be conducted by leading oncologists and cancer-care professionals and will include a physician-moderated online question-and-answer session for ASCO members. This new resource is available from ASCO OnLine, at www.asco.org.

Staying Current

ASCO Grand Rounds offers physicians an easy way to stay abreast of developments in cancer research. Each lecture consists of a 20- to 45-minute discussion that participants can listen to while viewing a synchronized slide presentation. Lectures will cover topics such as new drug development, cancer genetics, and supportive care and will be available throughout the year on ASCO’s website. Approximately two new lectures will be presented each month.

“We are excited that ASCO is taking a leading role in providing online education to oncologists around the world,” said ASCO president Joseph S. Bailes, MD.

Articles in this issue
Non–Small-Cell Lung Cancer Single-Agent Therapy
Linezolid-A New Option for Treating Gram-Positive Infections
Current Issues in the Treatment of Resistant Bloodstream Infections
Current Treatments for Infection in Neutropenic Patients With Hematologic Malignancy
Changing Patterns of Infections and Antimicrobial Susceptibilities
Ambulatory Antimicrobial Therapy for Hematologic Malignancies
Questions and Answers: Non–Small-Cell Lung Cancer
Questions and Answers: Small-Cell Lung Cancer
Irinotecan in Small-Cell Lung Cancer-Japanese Trials
Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
Phase I/II Trial of Irinotecan, Carboplatin, and Paclitaxel in Advanced or Metastatic NSCLC
Phase I/II Study of Weekly Irinotecan and Paclitaxel in Patients With SCLC
Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC
Extensive Small-Cell Lung Cancer: A Treatment Overview
Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Recent Videos
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides
2 KOLs are featured in this series
Related Content
The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.

SON-080 May Decrease Chemotherapy-Induced Peripheral Neuropathy

Ariana Pelosci
July 26th 2024
Article

The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

FDA Accepts Resubmitted BLA for Cosibelimab in Advanced Skin Cancer

Russ Conroy
July 26th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

ODAC Votes in Favor of New Perioperative NSCLC Trial Design Proposals

Russ Conroy
July 25th 2024
Article

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

Ozuriftamab Vedotin Gains FDA Fast Track Designation for Recurrent SCCHN

Roman Fabbricatore
July 25th 2024
Article

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.